Single User License
INR 8436
Site License
INR 16873
Corporate User License
INR 25309

Service Tax Additional

select a format
Price

Single User License
USD 125
Site License
USD 250
Corporate User License
USD 375

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


BioLineRx, Ltd. (BLRX)-Financial and Strategic SWOT Analysis Review

BioLineRx, Ltd. (BLRX)-Financial and Strategic SWOT Analysis Review


  Request for Sample Report

Executive Summary

BioLineRx, Ltd. (BLRX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioLineRx, Ltd. (BioLineRx) is a clinical stage bio-pharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company's product pipeline includes three primary clinical stage drug candidates, namely, BL-8040, for multiple cancer and hematological indications; BL-5010, for non-surgical removal of skin lesions and BL-7010, for celiac disease and gluten sensitivity. BioLineRx's pipeline comprises three other drug candidates, BL-9020, BL-8020 and BL-1040, which are in various stages of clinical and preclinical development. The company focuses mainly on cancer and immunology. The company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel. BioLineRx is headquartered in Jerusalem, Israel.

BioLineRx, Ltd. Key Recent Developments

Aug 11, 2016: BioLineRx Names Philip A. Serlin as Chief Executive Officer

Aug 11, 2016: BioLineRx Reports Second Quarter 2016 Financial Results

May 17, 2016: BioLineRx Reports First Quarter 2016 Financial Results

Mar 10, 2016: BioLineRx Reports Year End 2015 Financial Results

Dec 03, 2015: BioLineRx Establishes Oncology Scientific Advisory Board

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

BioLineRx, Ltd.-Key Facts 6

BioLineRx, Ltd.-Key Employees 7

BioLineRx, Ltd.-Key Employee Biographies 8

BioLineRx, Ltd.-Major Products and Services 9

BioLineRx, Ltd.-Pharmaceutical Pipeline Products Data 10

BioLineRx, Ltd., Pipeline Products by Therapy Area 10

BioLineRx, Ltd., Pipeline Products by Development Phase 11

BioLineRx, Ltd.-History 13

BioLineRx, Ltd.-Company Statement 19

BioLineRx, Ltd.-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Joint Venture 20

Section 2-Company Analysis 21

BioLineRx, Ltd.-Business Description 21

BioLineRx, Ltd.-Corporate Strategy 22

BioLineRx, Ltd.-SWOT Analysis 23

SWOT Analysis-Overview 23

BioLineRx, Ltd.-Strengths 23

Strength-EDP Program 23

Strength-Focused Research and Development 23

Strength-Patent Portfolio 23

BioLineRx, Ltd.-Weaknesses 24

Weakness-Lack of Marketed Products 24

Weakness-Competitive Positioning 24

Weakness-Discontinued Projects 24

BioLineRx, Ltd.-Opportunities 25

Opportunity-Orphan Drug Designation 25

Opportunity-Strategic Alliances and Collaborations 25

Opportunity-Products in Pipeline 25

BioLineRx, Ltd.-Threats 26

Threat-Competitive Pressures 26

Threat-Instability in Israel 26

Threat-Reliance on the Third Parties 26

BioLineRx, Ltd.-Key Competitors 27

Section 3-Company Financial Ratios 28

Financial Ratios-Capital Market Ratios 28

Financial Ratios-Annual Ratios 29

Performance Chart 30

Financial Performance 30

Financial Ratios-Interim Ratios 31

Financial Ratios-Ratio Charts 32

Section 4-Company's Lifesciences Financial Deals and Alliances 33

BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 34

BioLineRx, Ltd., Recent Deals Summary 35

Section 5-Company's Recent Developments 36

Aug 11, 2016: BioLineRx Names Philip A. Serlin as Chief Executive Officer 36

Aug 11, 2016: BioLineRx Reports Second Quarter 2016 Financial Results 37

May 17, 2016: BioLineRx Reports First Quarter 2016 Financial Results 39

Mar 10, 2016: BioLineRx Reports Year End 2015 Financial Results 41

Dec 03, 2015: BioLineRx Establishes Oncology Scientific Advisory Board 43

Nov 16, 2015: BioLineRx Reports Third Quarter 2015 Financial Results 45

Aug 20, 2015: BioLineRx Reports Second Quarter 2015 Financial Results 47

Aug 20, 2015: BioLineRx Reports Second Quarter 2015 Financial Results 49

May 18, 2015: BioLineRx Reports First Quarter 2015 Financial Results 51

Mar 23, 2015: BioLineRx Reports Year End 2014 Financial Results 53

Section 6-Appendix 56

Methodology 56

Ratio Definitions 56

About GlobalData 60

Contact Us 60

Disclaimer 60

List of Figures

BioLineRx, Ltd., Pipeline Products by Therapy Area 10

BioLineRx, Ltd., Pipeline Products by Development Phase 11

BioLineRx, Ltd., Performance Chart (2011-2015) 30

BioLineRx, Ltd., Ratio Charts 32

BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 34

List of Tables

BioLineRx, Ltd., Key Facts 6

BioLineRx, Ltd., Key Employees 7

BioLineRx, Ltd., Key Employee Biographies 8

BioLineRx, Ltd., Major Products and Services 9

BioLineRx, Ltd., Number of Pipeline Products by Therapy Area 10

BioLineRx, Ltd., Number of Pipeline Products by Development Stage 11

BioLineRx, Ltd., Pipeline Products By Therapy Area and Development Phase 12

BioLineRx, Ltd., History 13

BioLineRx, Ltd., Joint Venture 20

BioLineRx, Ltd., Key Competitors 27

BioLineRx, Ltd., Ratios based on current share price 28

BioLineRx, Ltd., Annual Ratios 29

BioLineRx, Ltd., Interim Ratios 31

BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 33

BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 34

BioLineRx, Ltd., Recent Deals Summary 35

Currency Codes 56

Capital Market Ratios 56

Equity Ratios 57

Profitability Ratios 57

Cost Ratios 58

Liquidity Ratios 58

Leverage Ratios 59

Efficiency Ratios 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

TaiGen Biotechnology Co., Ltd.

Polyphor Ltd.

Pertinax Therapeutics Inc.

MicroConstants China Inc.

LEO Pharma A/S

Genzyme Corporation

Eli Lilly and Company

BioLineRx, Ltd., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com